Stockholders Approve 3.4 Million Share Increase for Equity Incentive Plan
CLDX sits 75% above its 52-week low of $19.52.
Summary
Celldex Therapeutics stockholders approved a 3.4 million share increase for its equity incentive plan, representing a notable potential dilution for future employee compensation.
Key Events · Financing and Capital Events · CLDX
-
Equity Incentive Plan Expanded
Stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, adding 3,400,000 shares for future issuance. This brings the total shares reserved under the plan to 12,900,000.
-
Routine Governance Matters Approved
Stockholders also approved the election of directors, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor, and approved executive compensation on an advisory basis.
Analysis · CLDX · Life Sciences
Stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing the number of shares available for issuance by 3.4 million. This expansion, representing a notable potential dilution for existing shareholders, is primarily for employee compensation and retention. While dilutive, such plans are common for growth companies like Celldex, especially after recent positive clinical trial results and a significant capital raise.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLDX was trading at $34.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $19.52 to $35.79. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.